REGN Regeneron Pharmaceuticals, Inc.
$788.04
Regeneron Pharmaceuticals, Inc. (REGN) is confirmed to report earnings on October 30, 2026, before the market open. The consensus earnings estimate is $12.89 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +12.3% since its last earnings release on July 30, 2026.
Regeneron Pharmaceuticals Beat Expectations
Thursday, July 30, 2026 · 6:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Oct 30
Friday · 6:30 AM ET
Earnings Whisper
-
vs $12.89
(GAAP)
Rev est $4.43B
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$796.99
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals Inc is a fully integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Sector
Healthcare
Industry
Biotechnology
Held By 15 ETFs, by dollar flow
- QQQ Invesco QQQ Trust
- QQQ Invesco QQQ Trust
- XT iShares Exponential Technologies ETF
- XT iShares Exponential Technologies ETF
- QNXT iShares Nasdaq-100 ex Top 30 ETF
- QNXT iShares Nasdaq-100 ex Top 30 ETF
- IYH iShares U.S. Healthcare ETF
- IYH iShares U.S. Healthcare ETF
- XLV Health Care Select Sector SPDR Fund
- XLV Health Care Select Sector SPDR Fund
- IXJ iShares Global Healthcare ETF
- IXJ iShares Global Healthcare ETF
- BBH VanEck Biotech ETF
- BBH VanEck Biotech ETF
- IDNA iShares Genomics Immunology and Healthcare ETF
Charts powered in part by Lightweight Charts™ by TradingView.